Genzyme sues Lupin over Renagel patents
This article was originally published in Scrip
Executive Summary
Genzyme has filed a suit against Lupin in a federal court in Wilmington, Delaware, alleging patent infringement related to its generic version of Renagel (sevelamer), thus triggering the 30-month stay of approval while the legal challenge is fought.